4.4 Article

Epidemiologic contributions to recent cancer trends among HIV- infected people in the United States

期刊

AIDS
卷 28, 期 6, 页码 881-890

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0000000000000163

关键词

cancer; HIV; AIDS; statistical modeling; trends; United States

资金

  1. SEER Program of the National Cancer Institute, Connecticut [HHSN261201000024C]
  2. SEER Program of the National Cancer Institute, New Jersey [HHSN261201000027C, N01-PC-2010-0027]
  3. National Program of Cancer Registries of the Centers for Disease Control and Prevention, Colorado [U58 DP000848-04]
  4. National Program of Cancer Registries of the Centers for Disease Control and Prevention, Georgia [5U58DP003875-01]
  5. National Program of Cancer Registries of the Centers for Disease Control and Prevention, Michigan [5U58DP000812-03]
  6. National Program of Cancer Registries of the Centers for Disease Control and Prevention, New Jersey [1US58/DP0039311-01]
  7. National Program of Cancer Registries of the Centers for Disease Control and Prevention, Texas [5U58DP000824-04]
  8. state of New Jersey
  9. National Cancer Institute, National Institutes of Health

向作者/读者索取更多资源

Objective:HIV-infected people have elevated risk for some cancers. Changing incidence of these cancers over time may reflect changes in three factors: HIV population demographic structure (e.g. age distribution), general population (background) cancer rates, and HIV-associated relative risks. We assessed the contributions of these factors to time trends for 10 cancers during 1996-2010.Design:Population-based registry linkage study.Methods:We applied Poisson models to data from the U.S. HIV/AIDS Cancer Match Study to estimate annual percentage changes (APCs) in incidence rates of AIDS-defining cancers [ADCs: Kaposi sarcoma, non-Hodgkin lymphoma (NHL), and cervical cancer] and seven non-AIDS-defining cancers (NADCs). We evaluated HIV-infected cancer trends with and without adjustment for demographics, trends in background rates, and trends in standardized incidence ratios (SIRs, to capture relative risk).Results:Cancer rates among HIV-infected people rose over time for anal (APC 3.8%), liver (8.5%), and prostate (9.8%) cancers, but declined for Kaposi sarcoma (1996-2000: -29.3%; 2000-2010: -7.8%), NHL (1996-2003: -15.7%; 2003-2010: -5.5%), cervical cancer (-11.1%), Hodgkin lymphoma (-4.0%), and lung cancer (-2.8%). Breast and colorectal cancer incidence did not change over time. Based on comparison to adjusted models, changing demographics contributed to trends for Kaposi sarcoma and breast, colorectal, liver, lung, and prostate cancers (all P<0.01). Trends in background rates were notable for liver (APC 5.6%) and lung (-3.2%) cancers. SIRs declined for ADCs, Hodgkin lymphoma (APC -3.2%), and lung cancer (-4.4%).Conclusion:Demographic shifts influenced several cancer trends among HIV-infected individuals. Falling relative risks largely explained ADC declines, while background incidence contributed to some NADC trends.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Identification of Candidates for Longer Lung Cancer Screening Intervals Following a Negative Low-Dose Computed Tomography Result

Hilary A. Robbins, Christine D. Berg, Li C. Cheung, Anil K. Chaturvedi, Hormuzd A. Katki

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)

Article Oncology

Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial

Hilary A. Robbins, Hormuzd A. Katki, Li C. Cheung, Rebecca Landy, Christine D. Berg

JOURNAL OF THORACIC ONCOLOGY (2019)

Editorial Material Critical Care Medicine

Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol

Hilary A. Robbins, Matthew Callister, Peter Sasieni, Samantha L. Quaife, Li C. Cheung, Paul Brennan, Hormuzd A. Katki, Christine D. Berg, David Baldwin, Mattias Johansson

LANCET RESPIRATORY MEDICINE (2019)

Letter Oncology

Defining Equity in Eligibility for Cancer Screening

Hilary A. Robbins, Mattias Johansson

JAMA ONCOLOGY (2020)

Editorial Material Respiratory System

Biomarkers in lung cancer screening: the importance of study design

David R. Baldwin, Matthew E. Callister, Philip A. Crosbie, Emma L. O'Dowd, Robert C. Rintoul, Hilary A. Robbins, Robert J. C. Steele

EUROPEAN RESPIRATORY JOURNAL (2021)

Article Oncology

Using Prediction Models to Reduce Persistent Racial and Ethnic Disparities in the Draft 2020 USPSTF Lung Cancer Screening Guidelines

Rebecca Landy, Corey D. Young, Martin Skarzynski, Li C. Cheung, Christine D. Berg, M. Patricia Rivera, Hilary A. Robbins, Anil K. Chaturvedi, Hormuzd A. Katki

Summary: The draft 2020 USPSTF guidelines increased eligibility for lung cancer screening among minorities and Whites by similar proportions compared to the 2013 guidelines. However, the relative disparity in gainable life-years from screening between eligible Whites and minorities actually increased with the 2020 guidelines. Using the LYFS-CT model could help reduce disparities in screening eligibility by identifying high-benefit individuals regardless of race and ethnicity.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Article Oncology

Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom

Hilary A. Robbins, Karine Alcala, Anthony J. Swerdlow, Minouk J. Schoemaker, Nick Wareham, Ruth C. Travis, Philip A. J. Crosbie, Matthew Callister, David R. Baldwin, Rebecca Landy, Mattias Johansson

Summary: In UK cohorts, the ability of risk prediction models to classify future lung cancer cases as eligible for screening was best for LCDRAT/LCRAT, very good for PLCOm2012, and lowest for LLPv2. This highlights the importance of validating prediction tools in specific countries.

BRITISH JOURNAL OF CANCER (2021)

Correction Oncology

Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom (Apr, 10.1038/s41416-021-01278-0, 2021)

Hilary A. Robbins, Karine Alcala, Anthony J. Swerdlow, Minouk J. Schoemaker, Nick Wareham, Ruth C. Travis, Philip A. J. Crosbie, Matthew Callister, David R. Baldwin, Rebecca Landy, Mattias Johansson

BRITISH JOURNAL OF CANCER (2021)

Article Oncology

Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium

Hilary A. Robbins, Aida Ferreiro-Iglesias, Tim Waterboer, Nicole Brenner, Mari Nygard, Noemi Bender, Lea Schroeder, Allan Hildesheim, Michael Pawlita, Gypsyamber D'Souza, Kala Visvanathan, Hilde Langseth, Nicolas F. Schlecht, Lesley F. Tinker, Ilir Agalliu, Sylvia Wassertheil-Smoller, Eivind Ness-Jensen, Kristian Hveem, Sara Grioni, Rudolf Kaaks, Maria-Jose Sanchez, Elisabete Weiderpass, Graham G. Giles, Roger L. Milne, Qiuyin Cai, William J. Blot, Wei Zheng, Stephanie J. Weinstein, Demetrius Albanes, Wen-Yi Huang, Neal D. Freedman, Aimee R. Kreimer, Mattias Johansson, Paul Brennan

Summary: Seropositivity for HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. This study constructed an OPC risk prediction model and found that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Public, Environmental & Occupational Health

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

Hilary A. Robbins, Karine Alcala, Elham Khodayari Moez, Florence Guida, Sera Thomas, Hana Zahed, Matthew T. Warkentin, Karl Smith-Byrne, Yonathan Brhane, David Muller, Xiaoshuang Feng, Demetrius Albanes, Melinda C. Aldrich, Alan A. Arslan, Julie Bassett, Christine D. Berg, Qiuyin Cai, Chu Chen, Michael P. A. Davies, Brenda Diergaarde, John K. Field, Neal D. Freedman, Wen-Yi Huang, Mikael Johansson, Michael Jones, Woon-Puay Koh, Stephen Lam, Qing Lan, Arnulf Langhammer, Linda M. Liao, Geoffrey Liu, Reza Malekzadeh, Roger L. Milne, Luis M. Montuenga, Thomas Rohan, Howard D. Sesso, Gianluca Severi, Mahdi Sheikh, Rashmi Sinha, Xiao-Ou Shu, Victoria L. Stevens, Martin C. Tammemaegi, Lesley F. Tinker, Kala Visvanathan, Ying Wang, Renwei Wang, Stephanie J. Weinstein, Emily White, David Wilson, Jian-Min Yuan, Xuehong Zhang, Wei Zheng, Christopher I. Amos, Paul Brennan, Mattias Johansson, Rayjean J. Hung

Summary: The INTEGRAL program aims to develop tools for optimizing LDCT lung cancer screening. It includes the Risk Biomarker and Nodule Malignancy projects, which investigate circulating protein markers for identifying individuals likely to benefit from screening and distinguishing benign versus malignant nodules. A total of 1161 and 1078 proteins were measured, and 21 proteins were selected for performance evaluation in the Risk Biomarker and Nodule Malignancy projects.

ANNALS OF EPIDEMIOLOGY (2023)

Article Oncology

Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts

Wendy Yi-Ying Wu, Zahra Haider, Xiaoshuang Feng, Alicia K. Heath, Anne Tjonneland, Antonio Agudo, Giovanna Masala, Hilary A. Robbins, Maria-Jose Huerta, Marcela Guevara, Matthias B. Schulze, Miguel Rodriguez-Barranco, Paolo Vineis, Rosario Tumino, Rudolf Kaaks, Renee T. Fortner, Sabina Sieri, Salvatore Panico, Therese Haugdahl Nost, Torkjel M. Sandanger, Tonje Braaten, Mattias Johansson, Beatrice Melin, Mikael Johansson

Summary: The study evaluated the risk-discriminatory performance of the EarlyCDT-Lung test in ever-smokers and found that it is not effective in identifying high-risk individuals for lung cancer screening.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Smoking Cessation After Diagnosis of Kidney Cancer Is Associated With Reduced Risk of Mortality and Cancer Progression: A Prospective Cohort Study

Mahdi Sheikh, Anush Mukeriya, Hana Zahed, Xiaoshuang Feng, Hilary A. Robbins, Oxana Shangina, Vsevolod Matveev, Paul Brennan, David Zaridze

Summary: This study investigated the impact of smoking cessation after RCC diagnosis on the risk of death and disease progression. The results showed that quitting smoking was associated with lower risks of all-cause mortality, disease progression, and cancer-specific mortality among patients with RCC. This highlights the importance of smoking cessation in improving survival and reducing the risk of disease progression and cancer mortality.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Survival and prognostic factors of early-stage non-small cell lung cancer in Central and Eastern Europe: A prospective cohort study

Mahdi Sheikh, Shama Virani, Hilary A. Robbins, Lenka Foretova, Ivana Holcatova, Vladimir Janout, Jolanta Lissowska, Marie Navratilova, Anush Mukeriya, Miodrag Ognjanovic, Beata Swiatkowska, David Zaridze, Paul Brennan

Summary: This study investigated the survival and prognostic factors of surgically-resected early-stage non-small cell lung cancer (NSCLC) in Central and Eastern Europe. The 5-year survival rate was 49.5%, and age, gender, weight loss, smoking, alcohol drinking, and tumor stage were associated with the risk of death. Smoking and alcohol drinking showed a dose-dependent association with cancer-specific mortality.

CANCER MEDICINE (2023)

Article Oncology

Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study

Hana Zahed, Xiaoshuang Feng, Mahdi Sheikh, Freddie Bray, Jacques Ferlay, Ophira Ginsburg, Meredith S. Shiels, Hilary A. Robbins

Summary: This study examined the median age at diagnosis of common cancers worldwide and found that there are differences across countries. These differences likely arise from variations in risk factors and cancer control measures at the population level.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Circulating proteome for pulmonary nodule malignancy

Elham Khodayari Moez, Matthew T. Warkentin, Yonathan Brhane, Stephen Lam, John K. Field, Geoffrey Liu, Javier J. Zulueta, Karmele Valencia, Miguel Mesa-Guzman, Andrea Pasquier Nialet, Sukhinder Atkar-Khattra, Michael P. A. Davies, Benjamin Grant, Kiera Murison, Luis M. Montuenga, Christopher Amos, Hilary A. Robbins, Mattias Johansson, Rayjean J. Hung

Summary: The study found that circulating protein markers can help differentiate malignant from benign pulmonary nodules. Using blood samples from international low-dose computed tomography screening studies, 36 potential protein markers were identified. The protein burden scores for overall nodule malignancy and imminent tumors were summarized, with a focus on the significantly higher scores for malignant nodules in LungRADS category 4. However, further validation is needed before clinical implementation.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

暂无数据